SCHEMBL23218333

SCHEMBL23218333

COCCc1oc2ccc(Br)cc2c1C(=O)OC

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.48
MAPT P10636 4/20 0.48
HSD17B10 Q99714 3/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HPGD P15428 2/20 0.47
CA12 O43570 3/20 0.44
CA9 Q16790 3/20 0.44
TP53 P04637 1/20 0.44
ALOX5 P09917 3/20 0.42
HTT P42858 1/20 0.41
KCNH2 Q12809 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853212 1.00 TSHR (0.48) TSHRMAPTHSD17B10KDM4EALDH1A1
SCHEMBL23218696 0.88 MAPT (0.49) TSHRMAPTHSD17B10KDM4EALDH1A1
SCHEMBL29853044 0.88 MAPT (0.49) TSHRMAPTHSD17B10KDM4EALDH1A1
SCHEMBL29852438 0.85 SLC22A12 (0.53) TSHRMAPTHSD17B10KDM4EALDH1A1
SCHEMBL23218476 0.85 SLC22A12 (0.53) TSHRMAPTHSD17B10KDM4EALDH1A1
SCHEMBL29853045 0.78 GAA (0.55) TSHRMAPTHSD17B10KDM4EALDH1A1
SCHEMBL15020039 0.78 GAA (0.55) TSHRMAPTHSD17B10KDM4EALDH1A1
SCHEMBL23218325 0.77 MAPT (0.40) TSHRMAPTHSD17B10KDM4EALDH1A1
SCHEMBL29591980 0.77 MAPT (0.40) TSHRMAPTHSD17B10KDM4EALDH1A1
SCHEMBL23218840 0.75 SMN1; SMN2 (0.57) TSHRMAPTHSD17B10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TSHR 1199/4885MAPT 4793/4885HSD17B10 1149/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TSHR 3148/4885MAPT 3561/4885HSD17B10 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.